A client with plaque psoriasis is scheduled to start deucravacitinib. Which finding requires clarification before the first dose?
1Begin therapy after documenting the recent nonlive influenza vaccination.
2Begin therapy with breakfast and monitor for nausea during the first week.
3Delay therapy and clarify treatment of latent TB and timing of the live vaccine.✓ Correct answer
4Begin therapy after reinforcing routine skin care and infection precautions.
Explanation
Before deucravacitinib, the client requires evaluation for tuberculosis and completion of appropriate immunizations. Active tuberculosis is a stop condition, latent infection needs treatment planning, and live vaccines should be avoided during therapy.
Quick answer Clarify untreated tuberculosis risk and a planned live vaccine before deucravacitinib.
Why this is correct TYK2 inhibition can increase infection risk. Screening and preventive planning occur before immunomodulation; food timing and routine skin care do not create the same immediate safety conflict.
Easy analogy or mental picture Build a medication-safety chain: identify the new cue, connect it to the drug mechanism or labeled limitation, stop preventable exposure, stabilize the client, and verify a measurable response.
Memory hook Drug, urgent cue, protective action, and reassessment endpoint.
NCLEX decision rule Choose the action that prevents the most immediate medication-related harm while preserving indicated treatment and required monitoring.
Why the other choices are wrong Options that continue a suspect exposure, normalize a labeled danger cue, substitute an unauthorized dose, or delay escalation leave the client at risk.
References
1DailyMed: SOTYKTU (deucravacitinib)Infection and tuberculosis screening, serious-infection interruption, immunization planning, and avoidance of live vaccines
Medication-safety reviewVerify indication, current assessment, dose and route, organ function, interactions, urgent toxicity cues, authorized action, and measurable follow-up.